Optimizing development of anti-TNFα biosimilars based on 10 years’ experience
Routine regulatory requirements for large comparative efficacy trials (CETs) to support marketing approval of monoclonal antibody (mAb) biosimilars have been the focus of extensive debate in the last few years. This review examines the mounting evidence, accumulated over the past decade, focusing on...
Spremljeno u:
| Glavni autor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Open Exploration Publishing Inc.
2025-02-01
|
| Serija: | Exploration of Musculoskeletal Diseases |
| Teme: | |
| Online pristup: | https://www.explorationpub.com/uploads/Article/A100782/100782.pdf |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|